Roth Capital analyst Kyle Bauser raised the firm’s price target on iRadimed (IRMD) to $98 from $90 and keeps a Buy rating on the shares, citing higher forward estimates and confidence in the business after the company reported Q3 sales and EPS above the firm’s and consensus estimates and raised full-year guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRMD: